The Oncology Institute of Hope and Innovation Expands Research Partnership with Helios Clinical Across Markets, Enhancing Access to Cutting-Edge Cancer Trials
22 Abril 2025 - 5:05PM
The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the
“Company”), a pioneer in value-based community oncology care, is
proud to announce an enterprise-wide expansion of its strategic
partnership with Helios Clinical Research, a nationally recognized
research site network. This initiative builds upon a successful
collaboration in Florida and reflects TOI’s ongoing commitment to
integrating clinical research into community oncology settings.
“Expanding our research collaboration with Helios Clinical is a
natural next step,” said Daniel Virnich, MD, CEO at TOI. “They’ve
proven to be a highly capable partner, helping us streamline study
activation, accelerate enrollment, and reduce operational burden on
our sites. This move allows us to scale our research infrastructure
much more quickly while staying laser-focused on patient care.”
Strategic Benefits of the Partnership:
- Expanded Access to Clinical Trials:
Patients will gain greater access to leading-edge therapies through
trials supported by Helios’ centralized operations and outreach
model.
- Enhanced Trial Performance: Sponsors
benefit from streamlined startup processes, optimized patient
matching, and unified oversight.
- Scalable Infrastructure: Helios
provides regulatory, recruitment, and operational support, enabling
TOI’s clinicians to focus on delivering world-class care while
expanding their research footprint.
- Equity in Oncology Research: Both
organizations share a commitment to enrolling diverse and
underrepresented patient populations, advancing health equity in
oncology care.
“This isn’t just about geographic growth,” said Yale Podnos, MD,
Chief Medical Officer at TOI. “It’s about ensuring that clinical
research becomes a routine, integral part of patient care in every
market we serve.”
About The Oncology Institute
Founded in 2007, TOI is advancing oncology by delivering highly
specialized, value-based cancer care in the community setting. TOI
offers cutting-edge, evidence-based cancer care to a population of
over 1.8 million patients including clinical trials, transfusions,
and other services traditionally associated with the most advanced
care delivery organizations. With over 120 employed clinicians and
more than 700 teammates in over 70 clinic locations, TOI is
changing oncology for the better. For more information,
visit www.theoncologyinstitute.com
About Helios Clinical ResearchHelios Clinical
Research is a full-service site network known for its integrated,
tech-forward approach to clinical trial execution. With expertise
in oncology and a national footprint, Helios partners with leading
healthcare organizations to bring high-performing, patient-first
research capabilities into real-world care settings.
Contacts
Media
The Oncology Institute,
Inc.marketing@theoncologyinstitute.com
Investors
Solebury Strategic
Communicationsinvestors@theoncologyinstitute.com
Oncology Institute (NASDAQ:TOIIW)
Gráfico Histórico do Ativo
De Mai 2025 até Jun 2025
Oncology Institute (NASDAQ:TOIIW)
Gráfico Histórico do Ativo
De Jun 2024 até Jun 2025